Apomorphine is under clinical development by Alexza Pharmaceuticals and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Apomorphine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apomorphine overview

Staccato apomorphine is under development for the treatment of Parkinson's disease. The drug candidate is formulated as an aerosol for inhalation administration. It acts by targeting dopamine D1 and D2 receptors. The drug candidate is developed based on Staccato system technology.

Alexza Pharmaceuticals overview

Alexza Pharmaceuticals (Alexza), a subsidiary of Ferrer Therapeutics Inc, focuses on the research, development, and commercialization of novel, proprietary products for the treatment of acute central nervous system diseases. The company develops its products based on its own proprietary technology, the Staccato system (a hand-held inhaler), which is the foundation for Adasuve (loxapine) and all other product candidates. The company’s lead product Adasuve (Staccato loxapine) is indicated for the treatment of agitation associated with schizophrenia or bipolar I disorder. The company’s pipeline products include Staccato alprazolam intended for epileptic seizures; Staccato fentanyl for cancer breakthrough pain; Staccato apomorphine for the treatment of OFF episodes in patients with Parkinson’s disease, and Staccato granisetron for cyclic vomiting syndrome. Alexza is headquartered in Mountain View, California, the US.

For a complete picture of Apomorphine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.